Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech Stock
Biotech
Pliant terminates lung disease trial due to adverse events
Since the discontinuation was announced this morning, Pliant’s stock has halved.
Gabrielle Masson
Mar 3, 2025 11:30am
Why biotechs can benefit from the 'rational' IPO environment
Jan 24, 2025 10:30am
Galectin's stock halves after phase 3 MASH trial misses goal
Dec 20, 2024 2:40pm
Lumos stock rockets on oral growth hormone phase 2 results
Nov 8, 2023 9:40am
Enochian distances itself from co-founder amid short attack
Jun 2, 2022 10:53am
Zymeworks rejects All Blue's $773M offer as 'opportunistic'
May 20, 2022 10:56am
